Abstract：
This review aims to discuss recent research regarding the biomolecules explored in liquid biopsies and their potential clinical uses for adult-type diffuse gliomas.
Evaluation of tumor biomolecules via cerebrospinal fluid (CSF) is an emerging technology in neuro-oncology. Studies to date have already identified various circulating tumor DNA, extracellular vesicle, micro-messenger RNA and protein biomarkers of interest. These biomarkers show potential to assist in multiple avenues of central nervous system (CNS) tumor evaluation, including tumor differentiation and diagnosis, treatment selection, response assessment, detection of tumor progression, and prognosis. In addition, CSF liquid biopsies have the potential to better characterize tumor heterogeneity compared to conventional tissue collection and CNS imaging. Current imaging modalities are not sufficient to establish a definitive glioma diagnosis and repeated tissue sampling via conventional biopsy is risky, therefore, there is a great need to improve non-invasive and minimally invasive sampling methods. CSF liquid biopsies represent a promising, minimally invasive adjunct to current approaches which can provide diagnostic and prognostic information as well as aid in response assessment.
Evaluation of tumor biomolecules via cerebrospinal fluid (CSF) is an emerging technology in neuro-oncology. Studies to date have already identified various circulating tumor DNA, extracellular vesicle, micro-messenger RNA and protein biomarkers of interest. These biomarkers show potential to assist in multiple avenues of central nervous system (CNS) tumor evaluation, including tumor differentiation and diagnosis, treatment selection, response assessment, detection of tumor progression, and prognosis. In addition, CSF liquid biopsies have the potential to better characterize tumor heterogeneity compared to conventional tissue collection and CNS imaging. Current imaging modalities are not sufficient to establish a definitive glioma diagnosis and repeated tissue sampling via conventional biopsy is risky, therefore, there is a great need to improve non-invasive and minimally invasive sampling methods. CSF liquid biopsies represent a promising, minimally invasive adjunct to current approaches which can provide diagnostic and prognostic information as well as aid in response assessment.
摘要：
目的：这篇综述旨在讨论最近关于在液体活检中探索的生物分子及其在成人型弥漫性神经胶质瘤中的潜在临床应用的研究。
结果：通过脑脊液（CSF）评估肿瘤生物分子是神经肿瘤学中的新兴技术。迄今为止的研究已经确定了各种循环肿瘤DNA，细胞外囊泡，感兴趣的微信使RNA和蛋白质生物标志物。这些生物标志物显示出有助于中枢神经系统（CNS）肿瘤评估的多种途径的潜力，包括肿瘤的分化和诊断，治疗选择，反应评估,检测肿瘤进展，和预后。此外,与常规组织收集和CNS成像相比，CSF液体活检具有更好地表征肿瘤异质性的潜力。目前的成像模式不足以建立明确的神经胶质瘤诊断，通过常规活检重复组织取样是有风险的。因此,非常需要改进无创和微创采样方法。CSF液体活检代表了一个有希望的，微创辅助目前的方法，可以提供诊断和预后信息，以及帮助反应评估。
结果：通过脑脊液（CSF）评估肿瘤生物分子是神经肿瘤学中的新兴技术。迄今为止的研究已经确定了各种循环肿瘤DNA，细胞外囊泡，感兴趣的微信使RNA和蛋白质生物标志物。这些生物标志物显示出有助于中枢神经系统（CNS）肿瘤评估的多种途径的潜力，包括肿瘤的分化和诊断，治疗选择，反应评估,检测肿瘤进展，和预后。此外,与常规组织收集和CNS成像相比，CSF液体活检具有更好地表征肿瘤异质性的潜力。目前的成像模式不足以建立明确的神经胶质瘤诊断，通过常规活检重复组织取样是有风险的。因此,非常需要改进无创和微创采样方法。CSF液体活检代表了一个有希望的，微创辅助目前的方法，可以提供诊断和预后信息，以及帮助反应评估。
